Gisele Dion Net Worth

What's Gisele Dion's mailing address?

Gisele's mailing address filed with the SEC is 3350 RIVERWOOD PARKWAY SE, SUITE 1900, , ATLANTA, GA, 30339.

Insiders trading at Inhibikase Therapeutics

Over the last 4 years, insiders at Inhibikase Therapeutics have traded over $0 worth of Inhibikase Therapeutics stock and bought 47,537 units worth $63,897 . The most active insiders traders include Milton H. Werner, Elizabeth G. O'farrell, and Joseph Frattaroli. On average, Inhibikase Therapeutics executives and independent directors trade stock every 57 days with the average trade being worth of $22,267. The most recent stock trade was executed by Milton H. Werner on 16 August 2022, trading 5,000 units of IKT stock currently worth $4,000.

What does Inhibikase Therapeutics do?

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Inhibikase Therapeutics executives and stock owners

Inhibikase Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Milton H. Werner,
  CEO, Pres & Director
• Joseph Frattaroli CPA,
  Chief Financial Officer
• Dan Williams,
  Controller
• Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D.,
  Interim Chief Medical Officer & Science Advisor
• Dr. Surendra Singh,
  Head of Chemistry, Manufacturing & Controls
• Dr. Roger Rush,
  Head of Preclinical Research
• Garth Lees Rolfe,
  Chief Financial Officer
• Elizabeth G. O'farrell,
  Director
• Paul C Grint,
  
• Joseph Frattaroli,
  Cheif Financial Officer
• Roy Lester Freeman,
  
• Gisele Dion,
  
• Dennis N Berman,
  
• Milton H. Werner,
  President and CEO